DHA-PQP dispersible

Alfasigma

Legend
Product category

  • Artemisinin-based Combination Therapy (ACT)

  • Dihydroartemisinin-piperaquine
Therapeutic indication
  • Treatment of uncomplicated P. falciparum malaria in children and infants >5kg
Dosing

  • Once-daily for 3 days
Efficacy
  • Efficacy in adults established. PK bridging strategy to establish paediatric dose
Key features

  • Anticipated comparatively long post-treatment protection
Challenges

  • Cardiac monitoring restrictions 

  • Confirmed piperaquine resistance in Greater Mekong Sub-region (GMS)
Status

  • Pharmacokinetic studies in children completed 

  • Dossier under development for submission to EMA
Next milestone

  • Submission to EMA 
MMV Project Director
  • Adam Aspinall

* ACPR = adequate clinical and parasitological response